Dual RAAS suppression: recent developments and implications in light of the ALTITUDE study

J Renin Angiotensin Aldosterone Syst. 2012 Sep;13(3):409-12. doi: 10.1177/1470320312455271.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amides / pharmacology
  • Amides / therapeutic use*
  • Angiotensin Receptor Antagonists / pharmacology*
  • Angiotensin Receptor Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Angiotensinogen / metabolism
  • Animals
  • Blood Pressure
  • Clinical Trials Data Monitoring Committees
  • Congresses as Topic
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / physiopathology
  • Endpoint Determination
  • Fumarates / pharmacology
  • Fumarates / therapeutic use*
  • Heart Failure / drug therapy
  • Heart Failure / physiopathology
  • Humans
  • Randomized Controlled Trials as Topic*
  • Rats
  • Renin / metabolism
  • Renin-Angiotensin System / drug effects*

Substances

  • Amides
  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Fumarates
  • Angiotensinogen
  • aliskiren
  • Renin